Trial Profile
An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients with Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Sep 2019
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Sponsors AstraZeneca; Eli Lilly and Company (India) Pvt. Ltd
- 11 Jun 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01876849).
- 27 Jul 2011 New trial record